July 1, 2026
| Trial | TeLuRide-006 |
|---|---|
| Cancer Type | Skin Cancer and Melanoma |
| Hospital(s) | Belfast City Hospital |
| Information | Multicenter, Randomized, Double-Blind, Active Comparator-Controlled, Adaptive Phase 2/3 Study to Evaluate the Safety and Efficacy of EIK1001 and Pembrolizumab Versus Placebo and Pembrolizumab as First-Line Therapy in Participants with Advanced Melanoma |
| Trial Open | Yes |
 |
Click Here to view trial summary |